Due to the current situation related to the coronavirus (COVID-19), study teams may experience delays in responding to signups and scheduling patients on StudyPages.A study team member will respond to you as soon as possible. More coronavirus resources and updates from UC Davis Veterinary Medicine can be found here.

Evaluating early markers in blood and urine for acute kidney injury in horses

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
For questions and more information about this study, please contact the team using the information below.
Study coordinator
Name - Dr. Lais Costa
Email - lrcosta@ucdavis.edu
Phone - (610) 241-2645

Logo Image
"Help us find biomarkers to alert us about acute kidney injury in horses faster!"
Animal: Horses & Ponies
Age: None specified
Healthy Pets: No
Keywords: acute kidney injury, kidney, SDMA, NGAL, Cystatin C, KIM-1, equine, horse, biomarker
Type: Other
104 Participants
Background and purpose
The purpose of this study is to evaluate the usefulness of certain compounds in the blood and urine as biomarkers for kidney disease. These biomarkers (KIM-1, SDMA, NGAL, or Cystatin C) may be able to alert us to acute kidney disease before our currently available biomarkers (creatinine) can alert us.
What happens in this study

If you choose to have your horse participate in this clinical trial, and your horse is eligible to be included during your horse’s hospitalization, we will monitor biomarkers of kidney function daily in blood and urine. To do this, we will collect blood and urine daily and repeat the kidney ultrasound on the last day of relevant medication administration.

Pet owner responsibilities

Your horse will be a part of this study for a minimum of three days and a maximum of the duration of his or her hospitalization in which NSAIDs or aminoglycosides for the primary condition are administered. You will be responsible for covering the costs of your horse’s required hospitalization and associated treatments, but not for the samples collected for this study.

Participation requirements

Horses receiving medications that have potential kidney side effects, such as Non-Steroidal Anti-Inflammatory Drugs (Banamine, phenylbutazone, Equioxx) or aminoglycoside antibiotics (gentamicin or amikacin), or oxytetracycline.

Benefits and risks of participating
Your horse will receive a full kidney ultrasound, which could detect early kidney disease if indicated.
The study will cover all costs associated with the study including the kidney ultrasound and the sample collections of blood and urine. If your horse develops phlebitis (inflammation of the vein that occurs rarely with blood collections), the study will cover costs for medical treatment, including topical anti-inflammatory therapies.
Study duration and period
This study is designed to monitor the kidneys’ response to certain medications. Therefore, your horse will be a part of this study for a minimum of three days and a maximum of the duration of his or her hospitalization in which NSAIDs or aminoglycosides are administered, for a minimum of three days. After cessation of medication administration, your horse will be closely monitored for his or her primary condition as well as for signs of acute kidney injury.
Recruitment period
From April 6, 2018 to April 6, 2019
UC Davis Veterinary Medical Teaching Hospital
1 Garrod Drive
Large Animal Clinic - Equine Internal Medicine
Davis, CA 95616
Dr. Lais Costa

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview